Back to Journals » Drug Design, Development and Therapy » Volume 13

Letter regarding the article, “A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients”

Authors Zhao LY, Luo YJ, Zhu J

Received 25 August 2018

Accepted for publication 27 November 2018

Published 21 January 2019 Volume 2019:13 Pages 385—386


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Cristiana Tanase

Ling-Yue Zhao, Yi-Jun Luo, Jing Zhu

Department of Ambulatory Surgery, Shenzhen Nanshan District People’s Hospital, Shenzhen, Guangdong 518052, People’s Republic of China
Previous studies have confirmed the utility of canrenone to control inflammation, microalbuminuria, and cardiovascular risk.1,2 Recently, we read with great interest the study by Derosa et al.3 The authors performed a randomized, double-blind clinical trial to compare the effectiveness of canrenone vs hydrochlorothiazide (HCTZ) in addition to angiotensin II receptor blockers (ARBs) in patients with hypertension and type 2 diabetes mellitus. The primary endpoints were blood pressure, glycemia, lipid profile, potassium, aldosterone, and renal function. They concluded that the effect on blood pressure was similar between canrenone and HCTZ. Nevertheless, the metabolic parameters were improved in patients taking canrenone; thus, it was worsened in those receiving HCTZ. The research appears informative clinically. Thus, some issues should be addressed in interpreting the results.
View the original paper by Derosa and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]